<DOC>
	<DOCNO>NCT02473848</DOCNO>
	<brief_summary>The substance ingenol mebutate ( IM ) register Switzerland many country worldwide treatment actinic keratosis ( AK ) . There data use IM organ transplant recipient , population highly affect AK skin cancer large . The investigator want study use IM AK high-risk group patient assess safety . The investigator hop prove IM safe use AK organ transplant recipient , allow use clinical routine treatement AK also subset patient AK .</brief_summary>
	<brief_title>Ingenol Mebutate Gel 0.05 % Kidney Transplant Recipients With Actinic Keratoses</brief_title>
	<detailed_description>Ingenol mebutate gel , 0.05 % , commercially supply box 2 single use , unit dose tubes topical application 25cm2 , four conjunctive 25cm2 area ( 100cm2 ) treat . If 100 cm2 area clear Day 57 ( +/- 3 Days ) , second treatment cycle initiate commercially supply drug box 2 single use , unit dose tubes topical application 25cm2 four conjunctive 25cm2 area ( 100cm2 ) treat . In total first cycle , 4 commercially supply box ( 8 unit dose tube ) use , second cycle additional 4 commercially supply box ( 8 unit dose tube ) use ( total 8 box , 16 unit dose tube per patient ) .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Male subject 18 year age old Female subject 18 year age old nonchild bearing potential define serum follicle stimulate hormone ( FSH ) level â‰¥ 25.8 mIU/ml confirm clinical history sterility ( e.g . hysterectomy ) Renal transplantation perform two year inclusion Stable renal transplant function determine physician Actinic keratosis , one multiple , trunk and/or extremity , nonhypertrophic nonhyperkeratotic base clinical judgment within area 100 cm2 total ( several area add 100 cm2 permissible ) Signed Informed Consent oral write explanation study protocol contraindication ethical ground inability give inform consent woman childbearing potential , woman pregnant breast feed clinically significant concomitant disease ( e.g . hepatic dysfunction , cardiovascular disease , etc ) investigator 's discretion know suspected noncompliance , drug alcohol abuse enrolment clinical trial within last 4 week prior treatment ingenol mebutate gel prior local/topical treatment treatment area within 2 week trial entry : Dermabrasion , chemical peeling , laser treatment , cryotherapy surgery Imiquimod , diclofenac , 5Fluorouracil ( 5FU ) , topical corticosteroid , topical retinoids , treatment ultraviolet B ( UVB ) photodynamic treatment ( PDT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>